Channing Global Advisors LLC Sells 684 Shares of AstraZeneca PLC (NASDAQ:AZN)

Channing Global Advisors LLC lowered its holdings in AstraZeneca PLC (NASDAQ:AZN) by 10.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,864 shares of the company’s stock after selling 684 shares during the quarter. Channing Global Advisors LLC’s holdings in AstraZeneca were worth $457,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of AZN. Manning & Napier Advisors LLC purchased a new position in shares of AstraZeneca during the second quarter valued at approximately $188,476,000. Bank of Montreal Can boosted its holdings in AstraZeneca by 109.6% during the 3rd quarter. Bank of Montreal Can now owns 3,071,333 shares of the company’s stock worth $238,397,000 after acquiring an additional 1,605,758 shares during the last quarter. Hsbc Holdings PLC grew its stake in shares of AstraZeneca by 750.3% in the 2nd quarter. Hsbc Holdings PLC now owns 1,283,274 shares of the company’s stock worth $100,523,000 after acquiring an additional 1,132,362 shares in the last quarter. Farallon Capital Management LLC raised its holdings in shares of AstraZeneca by 65.1% in the second quarter. Farallon Capital Management LLC now owns 2,409,718 shares of the company’s stock valued at $187,934,000 after purchasing an additional 950,000 shares during the last quarter. Finally, Fisher Asset Management LLC lifted its position in shares of AstraZeneca by 5.3% during the third quarter. Fisher Asset Management LLC now owns 10,480,160 shares of the company’s stock valued at $816,509,000 after purchasing an additional 524,175 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Up 1.3 %

AZN stock opened at $67.20 on Friday. The stock has a fifty day moving average of $72.48 and a 200-day moving average of $77.50. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The company has a market capitalization of $208.36 billion, a price-to-earnings ratio of 32.15, a PEG ratio of 1.23 and a beta of 0.47. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. During the same quarter last year, the business earned $0.87 earnings per share. The company’s quarterly revenue was up 18.0% on a year-over-year basis. As a group, equities research analysts predict that AstraZeneca PLC will post 4.1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on AZN. TD Cowen increased their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Finally, UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.